Want to see SE:MODTX full AI Analyst Report?
Top Page
Modus Therapeutics Holding AB
(MODTX)
Select Model
Select Model
Rating:50Neutral
Price Target:
kr0.37
▲(24.33% Upside)
Action:Reiterated
Date:05/09/26
The score is primarily held back by weak financial performance (no revenue, ongoing losses, and rising cash burn), implying continued funding dependence. Technicals are moderately supportive with improving short- to mid-term momentum, but valuation signals are limited due to negative earnings and no dividend data.
Positive Factors
Low leverage / debt-free balance sheet
Reported zero total debt for 2023–2025 reduces bankruptcy and interest-rate risk and preserves flexibility. For an R&D-intensive biotech, low leverage supports the ability to pursue clinical programs or partnerships without near-term interest burdens, a durable financial advantage.
Negative Factors
Persistent and rising cash burn
Consistent negative operating and free cash flow, worsening to ~-SEK 18.1m in 2025, signals ongoing financing needs. For a clinical-stage biotech this increases dilution and refinancing risk, constraining strategic optionality and requiring external capital to sustain development programs.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / debt-free balance sheet
Reported zero total debt for 2023–2025 reduces bankruptcy and interest-rate risk and preserves flexibility. For an R&D-intensive biotech, low leverage supports the ability to pursue clinical programs or partnerships without near-term interest burdens, a durable financial advantage.
Read all positive factors
Modus Therapeutics Holding AB (MODTX) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr45.37M
Dividend YieldN/A
Average Volume (3M)841.43K
Price to Earnings (P/E)―
Beta (1Y)1.75
Revenue GrowthN/A
EPS Growth-28.21%
CountrySE
Employees2
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.15
Shares Outstanding121,628,494
10 Day Avg. Volume409,277
30 Day Avg. Volume841,432
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)2.10
Price to Sales (P/S)0.00
P/FCF Ratio-1.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.14
Revenue Forecast (FY)N/A
Modus Therapeutics Holding AB Business Overview & Revenue Model
Company Description
Modus Therapeutics Holding AB (publ), a biotechnology company, develops a treatment for sepsis and septic shock in Sweden. It develops Sevuparin, a lipopolysaccharide in Phase IIa trial to treat patients with sepsis, septic shock, anemia associate...
How the Company Makes Money
null...
Modus Therapeutics Holding AB Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
42
Neutral
Cash Flow
20
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -12.84M | -18.17M | -15.84M | 2.00K | -18.01M | -20.69M |
| Net Income | -12.94M | -18.54M | -15.54M | -17.90M | -18.32M | -20.69M |
Balance Sheet | ||||||
| Total Assets | 7.79M | 12.69M | 4.88M | 20.04M | 11.27M | 21.19M |
| Cash, Cash Equivalents and Short-Term Investments | 6.93M | 11.37M | 4.38M | 19.06M | 10.42M | 20.65M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 11.50M | 0.00 |
| Total Liabilities | 2.01M | 3.62M | 2.75M | 2.36M | 13.86M | 5.46M |
| Stockholders Equity | 5.79M | 9.07M | 2.14M | 17.68M | -2.58M | 15.73M |
Cash Flow | ||||||
| Free Cash Flow | -15.03M | -18.07M | -14.68M | -16.68M | -21.72M | -16.08M |
| Operating Cash Flow | -15.03M | -18.07M | -14.68M | -16.68M | -21.72M | -16.08M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -50.00K |
| Financing Cash Flow | 20.07M | 25.07M | 0.00 | 25.32M | 11.50M | 29.43M |
Modus Therapeutics Holding AB Technical Analysis
Negative
0.30
Price Trends
0.43
Negative
0.38
Negative
0.38
Negative
Market Momentum
-0.02
Positive
38.33
Neutral
31.24
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:MODTX, the sentiment is Negative. The current price of 0.3 is below the 20-day moving average (MA) of 0.41, below the 50-day MA of 0.43, and below the 200-day MA of 0.38, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 38.33 is Neutral, neither overbought nor oversold. The STOCH value of 31.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:MODTX.
Modus Therapeutics Holding AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | kr45.37M | -1.73 | -457.91% | ― | ― | -28.21% | |
49 Neutral | kr259.60M | -3.13 | -51.35% | ― | ― | 9.40% | |
49 Neutral | kr105.82M | -2.25 | -52.45% | ― | 7.80% | 42.81% | |
44 Neutral | kr195.54M | -9.84 | -59.78% | ― | ― | 43.32% | |
44 Neutral | kr149.07M | -244.78 | -1291.15% | ― | ― | 49.74% | |
41 Neutral | kr175.70M | -2.99 | ― | ― | -36.27% | 0.77% |
* Healthcare Sector Average
SE:MODTX
Modus Therapeutics Holding AB
0.37
-0.09
-18.74%
SE:ISOFOL
Isofol Medical AB
0.81
-0.05
-6.03%
SE:XINT
Xintela AB
0.20
-0.19
-48.61%
SE:ELIC
Elicera Therapeutics AB
2.93
-2.31
-44.11%
SE:ACTI
Active Biotech AB
5.66
-9.20
-61.93%
SE:NXTCL
NextCell Pharma AB
0.95
-0.10
-9.87%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.